Increasing evidence supports the human sodium-coupled citrate transporter (hNaCT) as a potential therapeutic target for metabolic syndrome and early infantile epileptic encephalopathy type 25 (EIEE25). While isotopic tracers remain the reference method for eva... ...

请注册登录后继续浏览